title: Development of a selective biopharmaceutical from Herpes simplex virus type 1 glycoproteins E and I for blocking antibody mediated neutralization of oncolytic viruses.
abstract: Future cancer therapies will be molecular cures. They will correct, block or destroy cancer cells by targeting molecular changes that lead to carcinogenesis. Destroying cancer cells can be done using oncolytic viruses. By blocking antibody mediated neutralization of oncolytic viruses, Herpes simplex virus type 1 glycoproteins E and I could be used in the adjuvant treatment of cancer for improving the chances of oncolytic viruses to kill cancer cells in vivo.
authors.affiliation: Rhoen Klinikum AG Hospital, Bad Neustadt ad Saale, Germany. s_bucurescu@yahoo.com
authors.forename: Septimiu
authors.initials: S
authors.lastname: Bucurescu
mesh_terms: D000818:Animals; D019138:Antibodies, Blocking / Q000276:immunology*; D057134:Antibodies, Neutralizing / Q000276:immunology*; D000914:Antibodies, Viral / Q000276:immunology; D002986:Clinical Trials as Topic; D018259:Herpesvirus 1, Human; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000628:therapy*; D050130:Oncolytic Virotherapy; D050504:Oncolytic Viruses / Q000276:immunology / Q000502:physiology*; D014759:Viral Envelope Proteins / Q000276:immunology / Q000378:metabolism / Q000627:therapeutic use*
chemical_list: D019138:Antibodies, Blocking; D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D014759:Viral Envelope Proteins; C044768:glycoprotein E, herpes simplex virus type 1; C064959:glycoprotein I, herpes simplex virus type 1